Pulmonx (LUNG) Enterprise Value (2019 - 2025)
Pulmonx (LUNG) has disclosed Enterprise Value for 7 consecutive years, with -$8.8 million as the latest value for Q2 2025.
- On a quarterly basis, Enterprise Value rose 92.35% to -$8.8 million in Q2 2025 year-over-year; TTM through Dec 2024 was -$101.5 million, a 13.34% increase, with the full-year FY2024 number at -$101.5 million, up 13.34% from a year prior.
- Enterprise Value was -$8.8 million for Q2 2025 at Pulmonx, up from -$14.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$8.8 million in Q2 2025 to a low of -$219.1 million in Q1 2021.
- A 5-year average of -$132.1 million and a median of -$138.1 million in 2022 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: tumbled 1248.85% in 2021, then soared 92.35% in 2025.
- Pulmonx's Enterprise Value stood at -$180.0 million in 2021, then increased by 21.61% to -$141.1 million in 2022, then increased by 17.03% to -$117.1 million in 2023, then increased by 13.34% to -$101.5 million in 2024, then surged by 91.37% to -$8.8 million in 2025.
- Per Business Quant, the three most recent readings for LUNG's Enterprise Value are -$8.8 million (Q2 2025), -$14.1 million (Q1 2025), and -$101.5 million (Q4 2024).